OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
1
Result
Show all
Save search
Copy query
Show results for
Unknown
(1)
Publication Date
Release Date
2022
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory
ALK
+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
Not available
S-EPMC9440305
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
